MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Kura Oncology Inc

Slēgts

SektorsVeselības aprūpe

6.38 0.47

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.26

Max

6.47

Galvenie mērījumi

By Trading Economics

Ienākumi

35M

-19M

Pārdošana

54M

54M

EPS

-0.22

Peļņas marža

-35.664

Darbinieki

192

EBITDA

43M

-17M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+287.76% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 1. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-114M

499M

Iepriekšējā atvēršanas cena

5.91

Iepriekšējā slēgšanas cena

6.38

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Kura Oncology Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 23:54 UTC

Karstas akcijas

Stocks to Watch: Alphabet, Intel, AppFolio

2025. g. 24. apr. 23:51 UTC

Tirgus saruna

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025. g. 24. apr. 23:37 UTC

Top Ziņas

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025. g. 24. apr. 23:36 UTC

Top Ziņas

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025. g. 24. apr. 23:13 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025. g. 24. apr. 23:09 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025. g. 24. apr. 22:51 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025. g. 24. apr. 22:48 UTC

Top Ziņas

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025. g. 24. apr. 22:47 UTC

Tirgus saruna

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025. g. 24. apr. 22:38 UTC

Tirgus saruna
Peļņas

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025. g. 24. apr. 22:24 UTC

Tirgus saruna
Peļņas

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025. g. 24. apr. 22:23 UTC

Peļņas

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025. g. 24. apr. 22:09 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025. g. 24. apr. 22:00 UTC

Tirgus saruna
Peļņas

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025. g. 24. apr. 21:39 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025. g. 24. apr. 21:23 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025. g. 24. apr. 21:04 UTC

Peļņas

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025. g. 24. apr. 21:02 UTC

Peļņas

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Salīdzinājums

Cenas izmaiņa

Kura Oncology Inc Prognoze

Cenas mērķis

By TipRanks

287.76% augšup

Prognoze 12 mēnešiem

Vidējais 24.7 USD  287.76%

Augstākais 40 USD

Zemākais 10 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Kura Oncology Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

10

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

5.77 / 6.41Atbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.